NEW YORK, Nov. 1 — Human Genome Sciences on Thursday announced that a monoclonal antibody product it developed has been approved by the US Food and Drug Administration to begin phase I trials, becoming the first drug candidate of its kind identified through genomics techniques to reach this stage.

The product, LymphoStat-B, will first be tested as a treatment for the autoimmune disease lupus. Clinical trials should begin by the new year, said company spokesperson Jerry Parrot. 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has approved Kite Pharmaceuticals' CAR T-cell therapy for large B-cell lymphomas, the New York Times reports.

Kaiser Health News reports that gene therapies could cost more than a million dollars.

Worcester Polytechnic Institute researchers have received a grant to combine biology and computer science for high school students.

In Nature this week: variants associated with obsessive-compulsive disorder, review of key CRISPR enzymes, and more.